Incannex Healthcare Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Incannex Healthcare Inc. (IXHL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $8.06 million for the 9-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2024-05-15
- Incannex Healthcare Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for the quarter ending 2024-03-31 was $3.07M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2024-03-31 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $8.06M 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $5.00M 10-Q · filed 2024-02-14 | ||||
| 2023-06-30 | $36.51M 10-Q · filed 2024-05-15 | $39.18M 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |